The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ages.

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis ...

Multiple myeloma is a cancer involving plasma ... according to the state health department. Nationwide, the American Cancer Society estimates that about 35,000 people will be diagnosed with ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier ...